Why the study?
Do NMDA antagonists improve outcomes in patients with ischemic stroke?
Population
Patients with ischemic stroke
Design
Review
Authors
Loading...
Adverse effects constrain NMDA antagonist use in ischemic stroke; leaves open whether optimized agents can deliver neuroprotection in ongoing trials.
Do NMDA antagonists improve outcomes in patients with ischemic stroke?
NMDA antagonists show experimental promise for neuroprotection in ischemic stroke, but clinical translation is limited by adverse effects, prompting ongoing large-scale trials.
Kennedy R. Lees (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: